Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Steroid-refractory Acute Graft-versus-Host Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01453140
What this trial is testing

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Who this might be right for
Graft Versus Host Disease
Hackensack Meridian Health 3
Large-scale testing (Phase 3)Study completedNCT02913261
What this trial is testing

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Who this might be right for
Corticosteroid Refractory Acute Graft vs Host Disease
Novartis Pharmaceuticals 310
Large-scale testing (Phase 3)Study completedNCT05663827
What this trial is testing

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Who this might be right for
Steroid Refractory GVHD
Yi-Lun Wang 6
Testing effectiveness (Phase 2)UnknownNCT04883918
What this trial is testing

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Who this might be right for
Acute-graft-versus-host Disease
ASC Therapeutics 60
Large-scale testing (Phase 3)Ended earlyNCT04934670
What this trial is testing

Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

Who this might be right for
Steroid-Refractory Acute Graft Versus Host Disease
Xenikos 12
Testing effectiveness (Phase 2)UnknownNCT04971551
What this trial is testing

Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Who this might be right for
Acute Graft-Versus-Host Disease
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 60
Not applicableApproved For MarketingNCT05722912
What this trial is testing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Who this might be right for
Graft-versus-host Disease (GVHD)
Incyte Corporation
Early research (Phase 1)Study completedNCT03327857
What this trial is testing

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Who this might be right for
Steroid-refractory Acute Graft-versus-Host DiseaseTreatment-refractory Acute Graft-versus-Host Disease
AltruBio Inc. 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07602751
What this trial is testing

FMT for Pediatric SR-aGVHD

Who this might be right for
Acute Graft Versus Host Disease in Intestine
Bambino Gesù Hospital and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT02997280
What this trial is testing

Ruxolitinib for Steroid-refractory GVHD

Who this might be right for
Graft Vs Host Disease
St. Petersburg State Pavlov Medical University 75
Large-scale testing (Phase 3)Not Yet RecruitingNCT07568535
What this trial is testing

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

Who this might be right for
GVHD - Graft-Versus-Host Disease
Mesoblast, Ltd. 180
Large-scale testing (Phase 3)Study completedNCT01442233
What this trial is testing

Plasma Exchanges in Multiple Sclerosis (MS) Relapses

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Acute Relapsing
University Hospital, Bordeaux 38
Testing effectiveness (Phase 2)Study completedNCT00201786
What this trial is testing

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Who this might be right for
Graft-Versus-Host Disease
Ohio State University Comprehensive Cancer Center 8
Testing effectiveness (Phase 2)Ended earlyNCT02322190
What this trial is testing

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Who this might be right for
Chronic Graft vs. Host DiseaseGraft vs Host DiseaseGraft-Versus-Host Disease
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07297069
What this trial is testing

Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

Who this might be right for
Acute Severe Ulcerative Colitis
Asian Institute of Gastroenterology, India 60
Not applicableAvailableNCT04745637
What this trial is testing

Managed Access Programs for INC424, Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)+4 more
Novartis Pharmaceuticals
Not applicableAvailableNCT04768907
What this trial is testing

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

Who this might be right for
Acute Graft Versus Host Disease in IntestineSteroid Refractory GVHD
MaaT Pharma
Post-approval studies (Phase 4)Study completedNCT02770040
What this trial is testing

Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis

Who this might be right for
Ulcerative Colitis
Austin Health 138
Testing effectiveness (Phase 2)Study completedNCT01700036
What this trial is testing

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

Who this might be right for
Graft vs Host Disease
University of Michigan Rogel Cancer Center 40